BTIG Reiterates Buy Rating on Verastem, Inc. (VSTM)
BTIG reaffirms its positive outlook on Verastem with an $18 price target, a 421.74% upside from the current price.
Key Points
- BTIG reiterated its buy rating for Verastem, Inc. (VSTM) with a price target of $18 on June 24, 2026.
- BTIG's $18 price target implies 421.74% upside from Verastem, Inc.'s ($VSTM) current $3.45 share price.
- Verastem shares traded at $4.21 on Wednesday, with a market cap of about $373.5 million and a 52-week range between $3.55 and $11.25.
- Insiders, including Michael Bailey, bought shares recently, and major funds like BlackRock increased their stakes.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Verastem, Inc. (NasdaqCM: VSTM), maintaining a price target of $18. This reaffirmation came on June 24, 2026, as analyst Jeet Mukherjee expressed continued confidence in the company's prospects.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Verastem, Inc.
Several major funds have been active in Verastem recently. BlackRock, Inc. added 1,442,083 shares, increasing its holdings by 30.3% to 6,194,925 shares, valued at about $32.8 million. Armistice Capital, LLC also increased its stake by 1,056,000 shares, a 29.9% boost, ending with 4,592,000 shares worth approximately $24.3 million. Nantahala Capital Management, LLC made a significant move, growing its position by 3,122,680 shares, a 675.7% increase, to hold 3,584,820 shares valued at $19 million.
Verastem, Inc. Stock Down 52.2%
Shares of Verastem, Inc. traded near $4.21 on Wednesday. The company has a market capitalization of about $373.5 million. Despite a negative forward P/E ratio due to unprofitability, the stock's beta is relatively low at 0.267, indicating less volatility. Its 52-week range spans from $3.55 to $11.25, with a 50-day moving average of $4.90 and a 200-day moving average of $7.04. The company's current ratio is 3.035, and its debt-to-equity ratio stands at 104.522.
$VSTM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Verastem reported revenue of $49.6 million, although it has not yet achieved profitability, as reflected by its negative return on equity of -7.86%. The company did not generate a net margin in the recent period. Investors are looking forward to the next earnings release, scheduled for August 6, 2026.
Insider Buying and Selling at Verastem, Inc.
On May 21, 2026, several insiders, including Michael Bailey, Karin Anna Tollefson, Anil Kapur, Eric Rowinsky, Brian Stuglik, and John Johnson, each bought 36,000 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, BTIG reiterated its buy rating with an $18 price target. Jefferies maintained its buy rating on June 23, 2026, with an $8 target. Mizuho also kept a buy rating with a $14 target on May 14, 2026. Overall, the consensus among eight analysts is a strong buy, with a mean price target of $16.
About Verastem, Inc.
Verastem, Inc. is a biopharmaceutical company based in Needham, Massachusetts. It focuses on developing and commercializing cancer therapies. Its lead product candidates include Avutometinib and Defactinib, targeting various cancer pathways. The company collaborates with major players like Pfizer and Amgen to enhance its drug development efforts. Verastem was founded in 2010 and employs around 102 people.
Bottom Line
BTIG's reiterated buy rating reflects its confidence in Verastem's potential, with an ambitious $18 price target. The company's ongoing collaborations and active insider buying suggest a commitment to advancing its cancer treatment pipeline. As always, investors should remember that analyst ratings are one of many factors to consider when evaluating a stock.
Get Verastem, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VSTM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.